CasCure Therapeutics

Main focus: Next-generation cell therapies for autoimmune diseases

Company stage: Pre-clinical

Diseases (gene editing): Solid tumours

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: Ulsan and Seoul, Korea

Website: http://cascure.com/

CasCure Therapeutics develops a novel method to selectively target and kill cancer cells using CRISPR-Cas9 technology.

Some of the best links we picked up around the internet

SNIPR Biome announced today that it has secured funding from CARB-X to further advance SNIPR001 into clinical trials in haematological cancer...

Some of the best links we picked up around the internet

New findings highlight a secondary conformational checkpoint in CRISPR-Cas9 that significantly enhances its accuracy in gene editing.

American researchers have developed a novel CRISPR-based platform to identify and characterise essential nutrient transporters that support cancer...

Tags